Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
172
resultados
Última actualización
27/07/2026 [08:08:00]
Resultados 75 a 100 de 172
Resumen de: WO2026137021A2
A cancer screening method takes advantage of the Warburg Effect to provide an early detection method and system. The cancer screening method includes administering a glucose solution, such as a C-13 glucose solution, measuring a metabolized lactate level in the blood of the individual after a period of time following the administration of the glucose solution, and comparing the measured lactate level to a baseline lactate level representative of noncancerous activity, and making a determination as to whether or not the measured lactate level is potentially indicative of cancer activity in the individual. The period of time is selected to be an amount of time following the glucose administration after which metabolized lactate from cancerous cells would be present in the blood and before which the metabolized lactate would be cleared or substantial amounts of non-cancerous metabolized lactate would be present in the blood of the individual.
Resumen de: US20260174959A1
0000 A glucose data analysis system includes an on-body unit and a processor. The on-body unit is configured to measure glucose levels of a user. The processor is configured to receive therapy data of the user including glucose data monitored by the on-body unit, analyze daily glucose profiles of the glucose data over an analysis period by a machine learning model, group the daily glucose profiles into two or more patterns based on the analysis performed by the machine learning model, and output a report including identification of the two or more patterns associated with each daily glucose profile. Advantageously the system may identify and visualize patterns of glucose data, identify recurring patterns, identify correlations between patterns and external events (e.g., medication, meals, exercise, sleep, stress, etc.), reduce glycemic variability, streamline analysis with unsupervised machine learning (e.g., no training), and provide recommendations for user intervention or actions based on identified patterns.
Resumen de: US20260174953A1
Embodiments disclosed herein are directed to an applicator for inserting a cannula into a body of the user for delivering medication from a medication infusion device to the user. According to one aspect, an applicator device includes a cannula and an insertion needle configured to insert the cannula into a body of a user. The applicator can include features that control the geometry of the skin during insertion of the cannula to provide a more reliable depth and insertion angle for the cannula.
Resumen de: WO2026136617A1
Provided herein is a noninvasive method for measuring pH, glucose and glycogen levels using a single acquisition method, as well as systems for performing the method. This method for glycogen/glucose (and pH) detection has high specificity enabled by superior chemical shift separation in high-strength magnetic fields. The methods have applications in detecting changing tumor microenvironments in cancerous cells for measuring important metrics for noninvasive and quantitative metabolic profiling.
Resumen de: US20260174360A1
Described herein are variations of an analyte monitoring system, including an analyte monitoring device. For example, an analyte monitoring device may include an implantable microneedle array for use in measuring one or more analytes (e.g., glucose), such as in a continuous manner. Each microneedle of the microneedle array may include a microneedle body, an electrode material on the microneedle body, a biorecognition layer on the electrode material, a diffusion-limiting layer on the biorecognition layer, an interferent blocking agent, and/or an attachment enhancer between the biorecognition layer and the diffusion-limiting layer, where the interferent blocking agent and the attachment enhancer are configured to improve sensor sensitivity variability.
Resumen de: US20260174399A1
Data describing glucose measurements is received from a continuous glucose monitoring (CGM) system worn by a user and predicted glucose values during a future time period are generated for the user based on the data. A determination is made that at least one of the predicted glucose values satisfies a threshold value for an alert, which is associated with a prediction horizon that defines an amount of time prior to satisfaction of the threshold value for communicating the alert to the user. Output of the alert is caused responsive to determining that the at least one predicted glucose value satisfies the threshold value for the alert within the prediction horizon, relative to a current time. The prediction horizon is modified based on a user response to the alert. Output of a subsequent instance of the alert is caused based on the modified prediction horizon.
Resumen de: US20260174960A1
Disclosed herein are systems and methods for the delivery of insulin and pramlintide using an automated insulin delivery system. In a first embodiment, a drug delivery system is configured to deliver independent doses of insulin and pramlintide. The system monitors the user's blood glucose level and determines when a meal is been ingested and, in response, delivers the dose of pramlintide which, in turn alters the required delivery of insulin. In the second embodiment, the drug delivery system is configured to deliver a co-formulation of insulin and pramlintide as basal doses. The total amount of pramlintide delivered in a most recent pre-determine period of time, for example, 24 hours, is used to alter the aggressiveness of the algorithm which determines the basal doses of the co-formulation.
Resumen de: US20260174969A1
0000 Diabetes management systems may include a glucose monitoring device adapted to transmit glucose data and at least one accessory in communication with the glucose monitoring device and adapted to provide at least one alarm or alert based on the glucose data.
Resumen de: AU2024395220A1
The present invention provides culture-derived berry cells compositions which have a high phenolic acid and low anthocyanins in their polyphenolic fraction, and are high in protein, low in sugar, and have a high antioxidation potential.
Resumen de: AU2024391032A1
Methods are disclosed for making a stem cell-derived islet-like cell (SC-IC) population, where such methods include culturing precursor cells such as pancreatic progenitor cells, pancreatic endocrine precursor cells or immature SC-ICs one or more differentiation mediums that promote the differentiation of the precursor cells to more differentiated cells to obtain an SC-IC population that includes mature pancreatic-beta-like cells. Also disclosed are cell-differentiating compositions useful in performing the methods and SC-IC populations obtained by performing the methods. Also disclosed are compositions and implantable devices comprising the SC-IC populations, which are useful thereof for treatment of metabolic disorders such as diabetes mellitus (diabetes).
Resumen de: US20260174803A1
0000 The present disclosure provides novel methods for increasing β-cell viability in islets by delivering RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, to the islets. The disclosure also provides novel methods for treating a disease or condition in a subject, such as type 1 diabetes mellitus, by delivering RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, to islets and transplanting the islets into the subject to treat the disease or condition. Kits and compositions including RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, are also provided to increase β-cell viability.
Resumen de: US20260174975A1
0000 This invention discloses a protective mechanism for insulin needles and an insulin injection device. Through the cooperation of a U-shaped reciprocating slot and a flexible wall, it is possible to automatically retract the needle tip after injection, and prevent it from being pushed out again, thus achieving the purpose of needle tip protection and avoiding reuse.
Resumen de: WO2026130307A1
Provided are small-fragment RNA derived from a circular RNA and the use thereof in the treatment of diabetic vascular diseases. The nucleotide sequence of the small-fragment RNA is CUAGCCGAAUGUUAAAAAAU. The provided small-fragment RNA has the effects of well protecting and maintaining the biological functions of vascular endothelial cells, has good structural stability, has a long half-life in vivo, and has the advantages of low effective concentration, high biological safety, etc. The provided small-fragment RNA has good application potentials in the field of clinical nucleic acid drug development, and provides a new idea for the treatment of chronic progressive vascular lesions caused by diabetes.
Resumen de: US20260174954A1
0000 An insulin delivery system for diabetes management includes a patch-based insulin pump configured to deliver insulin to a user, a user input button disposed on the patch-based insulin pump, a processor configured to execute a hybrid closed loop algorithm that automatically controls insulin delivery based on glucose levels. The user input button is configured to receive user input comprising a sequence of button presses that communicate contextual information about user activities to the hybrid closed loop algorithm, the contextual information being distinct from direct insulin bolus delivery commands. The contextual information may include meal intake, physical activity, and sleep status communicated through different sequences of button presses. The system includes confirmation mechanisms that provide feedback and allow cancellation of inputs, enabling discrete real-time communication of personalized data to enhance diabetes management.
Resumen de: WO2025038566A1
The exemplary embodiments may provide a correction factor (CF) for a user that is dynamically adjustable based on current glucose level. In some exemplary embodiments, the CF of the user is adjusted based on the current glucose level of the user. As the current glucose level of the user increases to be above a threshold, the CF may be adjusted to reflect a decrease in the insulin sensitivity of the user. This adjustment may cause the control system to increase the amount of insulin delivered to the user as the glucose level of the user exceeds the threshold. Similarly, the CF of the user may be adjusted based on the current target glucose level of the user or based on a combination of the current glucose level of the user and the current target glucose level of the user.
Resumen de: EP4765156A1
A blood glucose management method, a user interface, and a related apparatus are provided. According to the blood glucose management method, a first meal time can be determined based on historical blood glucose values of a user; a second meal time can be determined based on one or more of the following: a meal time input by the user, a hand movement of the user, and a heart rate of the user; and a third meal time can be determined based on the first meal time and the second meal time, where the third meal time is used to evaluate a blood glucose health status of the user. A meal time of the user is predicted based on historical meal times of the user that are determined in a plurality of manners, so that an electronic device can evaluate a blood glucose status of the user more accurately.
Resumen de: EP4765154A2
0001 An automated closed-loop blood glucose control system comprises a continuous glucose-monitoring sensor (101), a subcutaneous insulin delivery device (103); and a controller (105) which determines a maximal allowable insulin injection amount and determines an insulin delivery control signal on the basis of the maximal allowable insulin injection amount and the quantity of insulin to inject.
Resumen de: EP4763078A2
An example method for calibrating a glucose sensor includes determining, by one or more processors, a set of electrical parameters for the glucose sensor of a plurality of glucose sensors and determining, by the one or more processors, a cluster for the glucose sensor based on the set of electrical parameters. Each cluster of the plurality of clusters identifies respective configuration information. In this example, the method includes configuring, by the one or more processors, the glucose sensor to determine a glucose level of a patient based on configuration information identified by the determined cluster.
Resumen de: US12665067B1
Methods and systems are described for a computer-implemented method for managing behavior in a subject, the method comprising: monitoring a plurality of behavioral events, each event being correlated to a timestamp within a time period; identifying a pattern in the plurality of behavioral events; generating, based on the identified pattern, personalized content for the subject; generating one or more nudges for the subject based on the personalized content, wherein the one or more nudges comprise prompts or suggestions aimed at encouraging adherence to executing suggested behavior changes provided in the personalized content; and causing presentation of the personalized content and the one or more nudges to the subject.
Resumen de: US20260144222A1
0000 The present invention provides novel snap pea cultivar Sugar 204 and plant parts, seed, and tissue culture therefrom. The invention also provides methods for producing a pea plant by crossing the pea plants of the invention with themselves or another pea plant. The invention also provides pea plants produced from such a crossing as well as plant parts, seed, and tissue culture therefrom.
Resumen de: WO2021011738A1
A glucose level control system can autonomously modify therapy provided to a subject based on a comparison of the effect of different values for a control parameter. The system can deliver therapy to the subject during a first therapy period using a first value for the control parameter and determine a corresponding first effect to the first therapy by analyzing glycemic control of blood glucose in the subject. The system may autonomously generate a second value for the control parameter, and determine a second effect corresponding to a second therapy provided during a second time period using the second value. By comparing the effects of the two therapy periods, a value for the control parameter that provides improved blood glucose level management can be determined.
Resumen de: US20260165589A1
The present disclosure relates to a non-invasive sensing system for measuring key body vitals. The system includes a sensing device to generate a pre-processed signal in response to the lights reflected by the fingertips of a user. The pre-processed signal is received by a client application for extracting features using a pre-trained artificial intelligence (AI) based model to accurately measure at least six key body vitals including blood glucose, blood sugar (HBA1C), electrocardiogram (ECG), heart rate, blood oxygen level (SPo2), blood pressure, and body temperature. The system also includes a user interface, of the client application, to receive a request for the measured key body vitals and to output the measured key body vitals.
Resumen de: AU2026204177A1
Disclosed herein are an aqueous pharmaceutical formulation comprising cagrilintide and an aqueous formulation comprising semaglutide. The compositions of these two pharmaceutical formulations allow for their presentation in, and administration using, the dual-chamber medical device disclosed herein. Individuals with diseases, such as diabetes 5 and/or obesity and/or related co-morbidities, may benefit from the co-administration of semaglutide and cagrilintide, and/or of the two liquid pharmaceutical formulations disclosed herein, using the medical device disclosed herein. ay a y
Resumen de: US20260171205A1
Technologies are provided for insulin delivery. According to some aspects, a system may receive therapy-related data and settings associated with a first insulin infusion device used to deliver insulin to a user during a time period. The system may detect events during the period, via an event detection system, wherein each detected event comprises a specific activity that is indicative of a physical behavior of the user. The system may process the therapy-related data and settings to identify one or more physiological periods of the user, occurring during the time period, based on the detected events and the therapy-related data and settings, and may determine a physiological blood response of the user during the identified one or more physiological periods of the user. The system may output insulin delivery information for delivering insulin to the user based at least in part on the determined physiological blood response.
Nº publicación: US20260165622A1 18/06/2026
Solicitante:
UXN CO LTD [KR]
UXN CO., LTD
Resumen de: US20260165622A1
0000 This disclosure relates to a glucose-sensing electrode including a nanoporous metal layer and an electrolyte ion-blocking layer formed over the nanoporous metal layer. The nanoporous metal layer is capable of oxidizing both glucose and maltose without an enzyme specific to glucose in the glucose-sensing electrode. The electrolyte ion-blocking layer is configured to inhibit Na<+>, K<+>, Ca<2+>, Cl<−>, PO<4>3− and CO<3>2− from diffusing toward the nanoporous metal layer such that there is a substantial discontinuity of a combined concentration of Na<+>, K<+>, Ca<2+>, Cl<−>, PO<4>3− and CO<3>2− between over and below the electrolyte ion-blocking layer.
BOPI
Sede Electrónica
